期刊文献+

应用自制组织芯片研究抑癌基因PTEN在口腔鳞癌中的表达 被引量:4

Expression of Tumor Suppressor Gene PTEN in Oral Squamous Cell Cancer Using Tissue Microarray Techniques
下载PDF
导出
摘要 目的从蛋白水平探讨口腔鳞癌组织中肿瘤抑制基因PTEN的表达及临床病理意义。方法应用SP免疫组化染色法和组织芯片技术,检测10例正常口腔粘膜、10例口腔上皮单纯增生、15例口腔粘膜白斑及72例OSCC(其中高分化30例、中分化26例、低分化16例)组织中PTEN蛋白的表达,同时分析PTEN的表达与患者临床病理资料的关系。结果PTEN基因在口腔鳞癌、口腔粘膜白斑、口腔上皮单纯增生和正常口腔粘膜组织中的阳性率分别为72.2%(52/72)、93.3%(14/15)、100%(10/10)和100%(10/10),口腔鳞癌组与其他各组间有显著性差异(P<0.05);PTEN的阳性表达率在不同性别、年龄和TNM分期等临床病理参数间无显著性差异(P>0.05),但与淋巴结转移、组织分化程度等临床病理参数间有显著性差异(P<0.05)。结论PTEN基因表达的下调在OSCC的发生、发展中起着重要作用,其表达的异常可作为判断预后的参考指标之一。 Objective To explore expression of PTEN in oral squamous cell carcinoma (OSCC) and its clinicopathological significance Methods PTEN protein expression in paraffin embedded tissues from 10 cases of normal oral mucosa, 10 cases of oral epithelial hyperplasia, 15 cases of oral leukoplakia and 72 cases of OSCC was analyzed by SP immunohistochemical method and tissue microarray techniques, meanwhile analysed clinical pathological data. Results The positive rate of PTEN protein was 72. 2% (52/ 72) .93. 3% (14/15). 100% (10/10) and 100% (10/10) in OSCC, oral leukoplakia, oral epithelial hyperplasia and normal oral mucosa, there was significant correlation among them(P〈0. 05). PTEN expression was not obviously correlated with age, different gender, and TNM classification etc(P〉0. 05), but there was significant correlation with nodal metastases and degree of OSCC (P〈0. 05). Conclusion Loss of PTEN protein expression may play an important role on the tumorigenesis and development of OSCC, PTEN can be used as a reference marker for judging prognosis of patients with OSCC.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2007年第2期100-102,I0001,共4页 Cancer Research on Prevention and Treatment
关键词 PTEN 口腔鳞癌 组织芯片 免疫组化 PTEN OSCC Tissue microarray techniques Immunohistochemical method
  • 相关文献

参考文献8

  • 1Sallinen SL,Sallinen PK,Haapasalo HK,et al.Identification of Differentially Expressed Genes in Human Gliomas by DNA Microarray and Tissue Chip Techniques[J].Cancer Res,2000,60:6617-6622.
  • 2Moch H,Schraml P,Bubendorf L,et al.High-Throughput Tissue Microarray Analysis to Evaluate Genes Uncovered by cDNA Microarray Screening in Renal Cell Carcinoma[J].Am J Pathol,1999,154:981-986.
  • 3Lee JI,Soria JC,Hassan KA,et al.Loss of PTEN Expression as a Prognostic Marker for Tongue Cancer[J].Arch Otolaryngol Head Neck Surg,2001,127:1441-1445.
  • 4Shin KH,Kim JM,Rho KS,et al.Inactivation of the PTEN gene by mutation,exonic deletion,and loss of transcript in human oral squamous cell carcinomas[J].Int J Oncol,2002,21(5):997-1001.
  • 5Cairns P,Enron E,Okami K,et al.Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers[J].Oncogene,1998,6(24):3215-3218.
  • 6Mayo LD,Donner DB.The PTEN,Mdm2,p53 tumor suppressor oncoprotein network[J].Trends Biochem Sci,2002,27(9):462-467.
  • 7Squarize CH,Castilho RM,Santos D.Immunohistochemical evidence of PTEN in oral squamous cell carcinoma and its correlation with the histological malignancy grading system[J].J Oral Pathol Med,2002,31(7):379-384.
  • 8王颖,周传香,高文信.PTEN、p53在口腔黏膜白斑和口腔鳞癌组织中的表达及意义[J].口腔医学研究,2005,21(2):169-172. 被引量:9

二级参考文献10

  • 1Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer [J]. Science, 1997, 275(5308)∶1 943-1 947.
  • 2Wang SI, Puc J, Li J, et al. Somatic mutations of PTEN in glioblastoma multiforme [J]. Cancer Res, 1997, 57(19)∶4 183-4 186.
  • 3Mavros A, Hahn M, Wieland I, et al. Infrequent genetic alterations of the tumor suppressor gene PTEN/MMAC1 in squamous cell carcinoma of the oral cavity [J]. J Oral Pathol Med, 2002, 31(5)∶270-276.
  • 4Lee JI, Soria JC, Hassan KA, et al. Arch Otolaryngol Head Neck Surg, 2001, 127(12)∶1 441-1 445.
  • 5Maehama T, Dixon JE. PTEN: a tumour suppressor that functions as a phospholipid phosphatase [J]. Trends Cell Biol, 1999, 9(4)∶125-128.
  • 6Mayo LD and Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network [J]. Trends Biochem Sci, 2002, 27(9)∶462-467.
  • 7Koenig A, Bianco SR, Fosmire S, et al. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma [J]. Vet Pathol, 2002, 39(4)∶458-472.
  • 8Sheng X, Koul D, Liu JL, et al. Promoter analysis of tumor suppressor gene PTEN: identification of minimum promoter region [J]. Biochem Biophys Res Commun, 2002, 292(2)∶422-426.
  • 9Mayo LD, Dixon JE, Durden DL, et al. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy [J]. J Biol Chem, 2002, 277(7)∶5 484-5 489.
  • 10Stambolic V, MacPherson D, Sas D, et al. Regulation of PTEN transcription by p53 [J]. Mol Cell, 2001, 8(2)∶317-325.

共引文献8

同被引文献41

  • 1王颖,周传香,高文信.PTEN、p53在口腔黏膜白斑和口腔鳞癌组织中的表达及意义[J].口腔医学研究,2005,21(2):169-172. 被引量:9
  • 2谢思明,沈丽佳,殷操,阮萍,姚希.抑癌基因PTEN与PIP3、细胞周期蛋白D1在口腔鳞癌中的表达及其相关性分析[J].中华口腔医学杂志,2006,41(7):407-410. 被引量:11
  • 3房学东,任辉,张研,田宇.结直肠癌组织抑癌基因PTEN和癌基因C-myc蛋白表达及其相关性[J].吉林大学学报(医学版),2007,33(3):570-573. 被引量:7
  • 4Li J, Yen C, Liaw D, et al . PTEN, a putative protein tyrosine phos2phatase gene mutated in human brain, breast, and prostate carcinoma [J]. Science, 1997, 275 (5308) 943- 947.
  • 5Fei G, Ebert MP, Mawrin C, et al. Reduced PTEN expression in gastric carcinoma and in the gastric mucosa of gastric carcinoma relatives [J]. Eur J Gastroenterol Hepatol, 2002, 14 (3): 297 -303.
  • 6Lee JI, Soria JC, Hassan KA, et al. Loss of PTEN expression as aprognostic marker for tongue carcinoma [J].ArchOtolaryngol Head Neck Surg, 2001, 127 (12): 1441- 1445.
  • 7Maehama T, Dixon JE. PTEN; a tumor suppressor that functions as aphospholipid phosphatase [J]. Trends Cell Biol, 1999, 9 (4): 125-128.
  • 8Chen Q, Samaranayake LP, Zhou H, et al. Homozygous deletion of the PTEN tumor - suppressor gene is not a feature in oral squamous cellcarcinoma [J]. Oral Oncol, 2000, 36 (1): 95-99.
  • 9Wee K B, Aguda B D. Akt versus p53 in a network of oncogenes and tumor suppressor genes regulating cell survival and death[ J]. Biophys J, 2006, 91(3) : 857 -865.
  • 10Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer[J]. J Clin Oncol, 2009, 27 (35) : 5924 - 5930.

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部